Preview

PDF Restricted - Request a copy 198Kb

We aimed to assess the safety and efficacy of high-dose intermittent vitamin D supplementation in adolescents. Twenty-two healthy adolescents with serum 25 hydroxy-vitamin D (25-OHD) of 12.5–50 nmol/l were randomised to receive 300 000 IU or 150 000 IU of vitamin D3, or placebo orally 6-monthly for 1 year. At 12 months, the average vitamin D levels for the 300 000 IU, 150 000 IU and placebo groups were 63.0, 41.1 and 35.8 nmol/l, respectively, (P = 0.004 for difference between 300 000 IU group and placebo after adjustment for age, sex and seasonal variation). At 12 months, one participant receiving 300 000 IU was mildly deficient (25-OHD 49 nmol/l), whereas five out of six (83%) in the placebo and four out of seven participants (57%) in the 150 000 IU group remained deficient. There were no adverse events. Compliance was high. This suggests that 300 000 IU vitamin D3 orally 6-monthly may safely and effectively correct vitamin D deficiency in adolescents.

Item Type:	Refereed Article
Keywords:	vitamin D; children; clinical trials; osteoporosis
Research Division:	Biomedical and Clinical Sciences
Research Group:	Clinical sciences
Research Field:	Rheumatology and arthritis
Objective Division:	Health
Objective Group:	Clinical health
Objective Field:	Clinical health not elsewhere classified
UTAS Author:	Carnes, J (Mr Jonathan Carnes)
UTAS Author:	Nelson, M (Professor Mark Nelson)
UTAS Author:	Jones, G (Professor Graeme Jones)
UTAS Author:	Winzenberg, T (Professor Tania Winzenberg)
ID Code:	75744
Year Published:	2011
Web of Science® Times Cited:	16
Deposited By:	Menzies Institute for Medical Research
Deposited On:	2012-02-14
Last Modified:	2017-10-06
Downloads:	1 View Download Statistics